Literature DB >> 12419020

Pharmacokinetic scaling of bisphenol A by species-invariant time methods.

Chang Youn Cho1, Beom Soo Shin, Ji Hoon Jung, Dong Hwan Kim, Kang Choon Lee, Soon-Young Han, Hyung Sik Kim, Byung Mu Lee, Sun Dong Yoo.   

Abstract

1. The study was performed to predict the pharmacokinetic disposition of bisphenol A in humans using simple allometry and several species-invariant time methods based on animal data. Bisphenol A was injected intravenously to mouse, rat, rabbit and dog (1-2 mg kg(-1) doses). 2. The obtained serum concentration-time profiles were best described by bi-exponential equations in all these animal species, with the mean Cl, V(ss) and t(1/2) of 0.3 l h(-1), 0.1 litres and 39.9 min in mouse, 1.9 l h(-1), 1.3 litres and 37.6 min in rat, 12.6 l h(-1), 7.1 litres and 40.8 min in rabbit, and 27.1 l h(-1), 20.0 litres and 43.7 min in dog, respectively. 3. The human pharmacokinetic parameters of Cl, V(ss) and t(1/2) were predicted by simple allometry as well as by normalization according to species-invariant times of kallynochrons, apolysichrons and dienetichrons. 4. The simple allometric scaling and different time transformation methods predicted the human Cl, V(ss) and t(1/2) ranging from 46.0 to 127.1 l h(-1), 125.3 to 229.7 litres and 43.6 to 196.2 min, respectively. Species-invariant time transformations showed that all animal data from the four species were superimposable. These preliminary parameter values may be useful in interpreting toxicity data in humans on environmental exposure to bisphenol A.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12419020     DOI: 10.1080/00498250210163315

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  6 in total

1.  Prediction of human oral plasma concentration-time profiles using preclinical data: comparative evaluation of prediction approaches in early pharmaceutical discovery.

Authors:  An Van den Bergh; Vikash Sinha; Ron Gilissen; Roel Straetemans; Koen Wuyts; Denise Morrison; Luc Bijnens; Claire Mackie
Journal:  Clin Pharmacokinet       Date:  2011-08       Impact factor: 6.447

2.  Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data: what have we learned?

Authors:  Rong Deng; Suhasini Iyer; Frank-Peter Theil; Deborah L Mortensen; Paul J Fielder; Saileta Prabhu
Journal:  MAbs       Date:  2011-01-01       Impact factor: 5.857

3.  Probabilistic integrated risk assessment of human exposure risk to environmental bisphenol A pollution sources.

Authors:  Keng-Yen Fu; Yi-Hsien Cheng; Chia-Pin Chio; Chung-Min Liao
Journal:  Environ Sci Pollut Res Int       Date:  2016-07-16       Impact factor: 4.223

Review 4.  Critical evaluation of key evidence on the human health hazards of exposure to bisphenol A.

Authors:  J G Hengstler; H Foth; T Gebel; P-J Kramer; W Lilienblum; H Schweinfurth; W Völkel; K-M Wollin; U Gundert-Remy
Journal:  Crit Rev Toxicol       Date:  2011-04       Impact factor: 5.635

5.  Prediction of Human Pharmacokinetics of Antibody-Drug Conjugates From Nonclinical Data.

Authors:  Chunze Li; Cindy Zhang; Rong Deng; Douglas Leipold; Dongwei Li; Brandon Latifi; Yuying Gao; Crystal Zhang; Zao Li; Dale Miles; Shang-Chiung Chen; Divya Samineni; Bei Wang; Priya Agarwal; Dan Lu; Saileta Prabhu; Sandhya Girish; Amrita V Kamath
Journal:  Clin Transl Sci       Date:  2019-06-11       Impact factor: 4.689

6.  Pharmacokinetics of bisphenol A in humans following dermal administration.

Authors:  Alan F Sasso; Ralph Pirow; Syam S Andra; Rebecca Church; Rebecca M Nachman; Susanne Linke; Dustin F Kapraun; Shepherd H Schurman; Manish Arora; Kristina A Thayer; John R Bucher; Linda S Birnbaum
Journal:  Environ Int       Date:  2020-08-13       Impact factor: 13.352

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.